Q1 Earnings Forecast for TNYA Issued By William Blair

Key Points

• Tenaya Therapeutics is predicted to report a Q1 2026 EPS of ($0.30), with full-year earnings estimated at ($1.35) per share according to William Blair.
• The company last reported earnings on May 7th, missing analysts' expectations by $0.06 with an EPS of ($0.24).
• Six analysts rated TNYA as a “buy” with an average price target of $6.25, while the stock currently trades at around $0.67.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Equities researchers at William Blair issued their Q1 2026 earnings estimates for Tenaya Therapeutics in a report released on Wednesday, July 30th. William Blair analyst S. Corwin expects that the company will post earnings per share of ($0.30) for the quarter. The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($1.35) per share. William Blair also issued estimates for Tenaya Therapeutics' Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.29) EPS and FY2026 earnings at ($1.20) EPS.

A number of other equities analysts have also commented on the company. Chardan Capital reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Tenaya Therapeutics in a research note on Thursday. HC Wainwright reiterated a "buy" rating and set a $5.00 price objective on shares of Tenaya Therapeutics in a research note on Friday, April 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $6.25.

Tenaya Therapeutics Stock Down 2.9%

Shares of Tenaya Therapeutics stock traded down $0.02 during trading on Monday, hitting $0.66. The stock had a trading volume of 1,283,422 shares, compared to its average volume of 2,770,065. Tenaya Therapeutics has a 1 year low of $0.36 and a 1 year high of $4.01. The company has a market capitalization of $106.55 million, a PE ratio of -0.56 and a beta of 3.01. The stock has a 50 day simple moving average of $0.66 and a 200 day simple moving average of $0.68.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.06.

Hedge Funds Weigh In On Tenaya Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Commonwealth Equity Services LLC purchased a new stake in Tenaya Therapeutics during the fourth quarter valued at about $64,000. Sei Investments Co. bought a new position in shares of Tenaya Therapeutics in the fourth quarter worth about $100,000. JPMorgan Chase & Co. raised its holdings in Tenaya Therapeutics by 20,670.3% in the 4th quarter. JPMorgan Chase & Co. now owns 5,155,596 shares of the company's stock valued at $7,373,000 after acquiring an additional 5,130,774 shares in the last quarter. Mariner LLC acquired a new position in Tenaya Therapeutics in the fourth quarter worth $30,000. Finally, Commerce Bank acquired a new stake in Tenaya Therapeutics in the fourth quarter worth about $29,000. 90.54% of the stock is owned by institutional investors and hedge funds.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.